<SEC-DOCUMENT>0000950170-24-070875.txt : 20240607
<SEC-HEADER>0000950170-24-070875.hdr.sgml : 20240607
<ACCEPTANCE-DATETIME>20240607171619
ACCESSION NUMBER:		0000950170-24-070875
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240605
FILED AS OF DATE:		20240607
DATE AS OF CHANGE:		20240607

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Calhoun Lesley Ann
		CENTRAL INDEX KEY:			0001730866
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39485
		FILM NUMBER:		241030682

	MAIL ADDRESS:	
		STREET 1:		C/O GLOBAL BLOOD THERAPEUTICS, INC.
		STREET 2:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tango Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		201 BROOKLINE AVENUE
		STREET 2:		SUITE 901
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215
		BUSINESS PHONE:		(857) 320-4900

	MAIL ADDRESS:	
		STREET 1:		201 BROOKLINE AVENUE
		STREET 2:		SUITE 901
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BCTG Acquisition Corp.
		DATE OF NAME CHANGE:	20200723
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-05</periodOfReport>

    <issuer>
        <issuerCik>0001819133</issuerCik>
        <issuerName>Tango Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>TNGX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001730866</rptOwnerCik>
            <rptOwnerName>Calhoun Lesley Ann</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TANGO THERAPEUTICS, INC</rptOwnerStreet1>
            <rptOwnerStreet2>201 BROOKLINE AVE., SUITE 901</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02215</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-06-05</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>6250</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>11250</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-06-05</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>7.2078</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>6250</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>7.41</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-06-05</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>37500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-06-05</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>37500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>37500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These shares are represented by restricted stock units (the &quot;RSUs&quot;). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.</footnote>
        <footnote id="F2">The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2023.</footnote>
        <footnote id="F3">Represents the weighted average sales price per share. The shares sold at prices ranging from $7.01 to $7.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.</footnote>
        <footnote id="F4">This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Douglas Barry, as attorney-in-fact</signatureName>
        <signatureDate>2024-06-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
